Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm
- 1 May 2019
- journal article
- review article
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 13 (3) , 1935-1942
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes, Obesity and Metabolism, 2013
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart FailureCirculation: Heart Failure, 2011
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and ExerciseDiabetes Care, 2010
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- Metformin Therapy and Outcomes in Patients With Advanced Systolic Heart Failure and DiabetesJournal of Cardiac Failure, 2010
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic reviewBMJ, 2007